Missouri and Massachusetts escalate the fight over Eli Lilly’s 340B claims-data policy
Eli Lilly’s push to condition 340B drug discounts on claims-level data is drawing a faster, sharper legal response. This week, Missouri’s attorney general and six Massachusetts hospitals moved against the policy in separate actions, each arguing that the company has crossed the line from program oversight into coercive control over hospital purchasing and patient data.
The dispute centers on a policy Lilly announced in January and began applying to a subset of hospitals in June. Under the rule, providers must submit claims-level data before receiving statutory discounts for both pharmacy and medical dispensations, including in-house and contract pharmacy claims in most states. Lilly says the data lets it identify instances in which a drug is being discounted more than once through overlapping programs. Hospitals see something very different: a demand they describe as unnecessary, costly, and legally overreaching.
The tension is immediate. Hospitals depend on 340B savings to support care for low-income and rural patients. Lilly is insisting on a layer of data review it says is needed to protect the integrity of the discount structure. Those positions collide at the bedside, where higher acquisition costs can mean fewer clinics, fewer services, and tighter margins for already strained systems.
Missouri’s attorney general threatens injunctions and penalties
Missouri Attorney General Catherine Hanaway sent Lilly a cease-and-desist letter on Monday, arguing that the policy violates the Missouri Merchandising Practices Act. The letter warns that if the company does not end the requirement for Missouri providers, the state may pursue further legal action, including an injunction and monetary civil penalties.
Hanaway’s office framed the dispute as a misuse of market power. In a release accompanying the letter, she said Lilly was abusing its position to impose higher prescription prices in Missouri and that the burden falls especially hard on rural communities that rely on 340B savings to keep clinics open. The letter points to the company’s earlier decision to end discounts for University of Missouri Health Care in July. The system later agreed to provide the requested data, but the attorney general’s office said it still bears the operational costs and compliance burden created by Lilly’s terms.
The exchange captures the practical pressure hospitals face. Lose the discount, and acquisition costs rise immediately. Accept the policy, and the institution must absorb the cost of compliance, privacy oversight, and operational review. There is no easy off-ramp once a hospital depends on the savings to fund services.
Massachusetts hospitals accuse Lilly of coercion and privacy risk
A day later, six Massachusetts hospitals filed a federal lawsuit to block the policy: Massachusetts General Hospital, Brigham and Women’s Hospital, Salem Hospital, UMass Memorial Medical Center, and UMass Memorial Health — Harrington Hospital were among the plaintiffs. Their complaint describes what they call “corporate extortion” by the largest pharmaceutical company in the world, arguing that the policy strips resources from institutions serving vulnerable patients.
The hospitals say they refused to comply and then lost their 340B discounts, echoing earlier litigation brought by Tampa General Hospital and Mary Hitchcock Memorial Hospital. In the Massachusetts filing, the hospitals argue that resistance to the policy would cost them tens of millions of dollars in annual losses collectively. That figure is central to the case because it translates a legal dispute into operating reality: every dollar withheld from the discount program is a dollar that can no longer be used to offset drug costs, support clinic operations, or subsidize uncompensated care.
The lawsuit also attacks Lilly’s 340B ESP platform, which the hospitals describe as a privately owned, third-party system that functions as a data dragnet. The complaint says the platform’s claim to de-identify submitted claims data is superficial and that its non-negotiable terms allow Lilly to use the data beyond integrity review. It also says the contract limits Lilly’s liability to $100 while leaving hospitals with the full burden of privacy, cybersecurity, and regulatory compliance risk.
A single contractual clause can shift the entire balance of risk. In this dispute, hospitals say they are being forced to hand over protected health information without meaningful bargaining power while also carrying the consequences if something goes wrong.
340B’s growth has made the legal stakes larger
The broader 340B program has ballooned in scale over the last several years, and that growth has deepened the conflict between manufacturers and providers. Drugmakers critical of the program have tried to restrict contract pharmacy arrangements, triggering litigation in states where lawmakers have prohibited such limits. Policymakers have also pushed rebate-based pilots and other reforms, adding another layer of dispute over how savings should flow and who should oversee them.
Lilly has historically disputed hospitals’ characterization of its policy in prior litigation and has said the required data is already routinely collected by organizations. That defense matters because it frames the company’s approach as a verification process rather than a new burden. Hospitals reject that premise. They argue that routine collection inside a health system is not the same as surrendering claims data to a manufacturer-controlled platform under terms the hospitals cannot negotiate.
The legal fight is now increasingly about where accountability sits. If a manufacturer says it needs claims-level information to prevent duplicative discounts, then the question becomes how much data is enough, who controls it, and what protections apply once it leaves the hospital. If hospitals are correct, the policy is not a safeguard at all but a mechanism to choke off access to savings unless providers agree to intrusive terms.
The latest filings do not resolve any of those questions. They do make the contours of the dispute harder to ignore: a state attorney general threatening enforcement, major academic hospitals seeking injunctive relief, and a drugmaker defending a policy that has already become a template for broader 340B battles. The next court rulings will determine whether Lilly can keep tying discounts to claims-data submission in Missouri and Massachusetts, or whether the policy is forced to retreat under mounting legal pressure.